DB
PTCT icon

Dmitry Balyasny’s PTC Therapeutics PTCT Stock Holding History

Dmitry Balyasny’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-200,000
Closed -$6.75M – 1968
2018
Q2 		$6.75M Buy
+200,000
New +$6.24M 0.03% 595
2016
Q4 		– Sell
-96,274
Closed -$238K – 1458
2016
Q3 		$238K Buy
+96,274
New +$783K ﹤0.01% 852
2015
Q2 		– Sell
-57,000
Closed -$3.47M – 1286
2015
Q1 		$3.47M Buy
+57,000
New +$3.48M 0.03% 539

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Dmitry Balyasny's PTCT Position: Q2 2026 in Review

Dmitry Balyasny reduced its PTC Therapeutics (PTCT) stake by 96% in Q2 2026, selling an estimated $31.8M and leaving 20,605 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1910.

Dmitry Balyasny first reported a position in PTCT in Q2 2014 and has held it in 23 quarters since. The position peaked at $32.9M in Q3 2018. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Dmitry Balyasny held 20,605 shares of PTC Therapeutics worth $1.68M as of Q2 2026.
  • Dmitry Balyasny sold 439,959 PTC Therapeutics shares in Q2 2026, an estimated $31.8M.
  • PTC Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1910 holding.
  • Dmitry Balyasny first reported a position in PTC Therapeutics in Q2 2014 and has held it in 23 quarters since.
  • Dmitry Balyasny's PTC Therapeutics position peaked at $32.9M in Q3 2018.
  • 380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.